These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12243005)

  • 1. [Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002].
    Rieckmann P; Toyka KV;
    Nervenarzt; 2002 Jun; 73(6):556-63. PubMed ID: 12243005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
    Rieckmann P; Toyka KV; Bassetti C; Beer K; Beer S; Buettner U; Chofflon M; Götschi-Fuchs M; Hess K; Kappos L; Kesselring J; Goebels N; Ludin HP; Mattle H; Schluep M; Vaney C; Baumhackl U; Berger T; Deisenhammer F; Fazekas F; Freimüller M; Kollegger H; Kristoferitsch W; Lassmann H; Markut H; Strasser-Fuchs S; Vass K; Altenkirch H; Bamborschke S; Baum K; Benecke R; Brück W; Dommasch D; Elias WG; Gass A; Gehlen W; Haas J; Haferkamp G; Hanefeld F; Hartung HP; Heesen C; Heidenreich F; Heitmann R; Hemmer B; Hense T; Hohlfeld R; Janzen RW; Japp G; Jung S; Jügelt E; Koehler J; Kölmel W; König N; Lowitzsch K; Manegold U; Melms A; Mertin J; Oschmann P; Petereit HF; Pette M; Pöhlau D; Pohl D; Poser S; Sailer M; Schmidt S; Schock G; Schulz M; Schwarz S; Seidel D; Sommer N; Stangel M; Stark E; Steinbrecher A; Tumani H; Voltz R; Weber F; Weinrich W; Weissert R; Wiendl H; Wiethölter H; Wildemann U; Zettl UK; Zipp F; Zschenderlein R; Izquierdo G; Kirjazovas A; Packauskas L; Miller D; Koncan Vracko B; Millers A; Orologas A; Panellus M; Sindic CJ; Bratic M; Svraka A; Vella NR; Stelmasiak Z; Selmaj K; Bartosik-Psujik H; Mitosek-Szewczyk K; Belniak E; Mochecka A; Bayas A; Chan A; Flachenecker P; Gold R; Kallmann B; Leussink V; Mäurer M; Ruprecht K; Stoll G; Weilbach FX;
    J Neurol; 2004 Nov; 251(11):1329-39. PubMed ID: 15592728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Beta-interferons in multiple sclerosis: comparative trials and potential individual selection in different types of the disease course].
    Boĭko AN; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():65-71. PubMed ID: 12418395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].
    Multiple Sklerose-Therapie-Konsensus Gruppe (MSTKG)
    Nervenarzt; 2001 Feb; 72(2):150-7. PubMed ID: 11256151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ALEMTUZUMAB: BENEFITS AND CHALLENGES OF A NEW THERAPY IN MULTIPLE SCLEROSIS].
    Illés Z; Sejbaek T; Csépány T
    Ideggyogy Sz; 2015 May; 68(5-6):155-64. PubMed ID: 26182606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.
    Brown MG; Murray TJ; Sketris IS; Fisk JD; LeBlanc JC; Schwartz CE; Skedgel C
    Int J Technol Assess Health Care; 2000; 16(3):751-67. PubMed ID: 11028131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
    ; Rieckmann P
    Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
    Johnson KP; Due DL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta in multiple sclerosis: predicting response at an early stage.
    Killestein J; Hartung HP
    J Neurol Neurosurg Psychiatry; 2008 Jun; 79(6):616-7. PubMed ID: 18487553
    [No Abstract]   [Full Text] [Related]  

  • 18. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
    Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
    Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Choice of early and escalation treatment options for multiple sclerosis].
    Linker RA; Kieseier BC
    Nervenarzt; 2008 Oct; 79(10):1123-4,1126-8,1130-2 passim. PubMed ID: 18806985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.
    Janković SM; Kostić M; Radosavljević M; Tesić D; Stefanović-Stoimenov N; Stevanović I; Raković S; Aleksić J; Folić M; Aleksić A; Mihajlović I; Biorac N; Borlja J; Vucković R
    Vojnosanit Pregl; 2009 Jul; 66(7):556-62. PubMed ID: 19678581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.